Morphological alterations of exogenous surfactant inhibited by meconium can be prevented by dextran
Tóm tắt
Surfactant dysfunction due to inhibition is involved in the pathophysiology of meconium aspiration syndrome. Dextran addition has been shown to reverse exogenous surfactant inactivation by meconium, but the precise mechanisms and the morphological correlate of this effect are yet unknown. Morphological surfactant analysis by transmission electron microscopy (TEM) and stereology allows the differentiation of active (large aggregates = LA) and inactive (small aggregates = SA) subtypes. To determine the in vitro effects of meconium and dextran addition on the morphology of a modified porcine natural surfactant (Curosurf), Curosurf samples were either incubated alone or together with meconium or with meconium and dextran, fixed and processed for TEM. Volume fractions of surfactant subtypes [lamellar body-like forms (LBL), multilamellar vesicles (MV), unilamellar vesicles (UV)] were determined stereologically. All preparations contained LBL and MV (corresponding to LA) as well as UV (corresponding to SA). The volume fraction of UV increased with addition of meconium and decreased with further addition of dextran. Correspondingly, the UV/(LBL+MV) ratio (resembling the SA/LA ratio) increased when meconium was added and decreased when dextran was added to the surfactant-meconium mixture. Meconium causes alterations in the ultrastructural composition of Curosurf that can be visualized and analyzed by TEM and stereology. These alterations resemble an increase in the SA/LA ratio and are paralleled by an increase in minimum surface tension. Dextran prevents these effects and may therefore be a useful additive to exogenous surfactant preparations to preserve their structural and functional integrity, thereby improving their resistance to inactivation.
Tài liệu tham khảo
Notter RH: Lung surfactants. Basic science and clinical applications. Lung biology in health and disease. Volume 149. New York: Marcel Dekker; 2000.
McCormack FX, Whitsett JA: The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J Clin Invest 2002, 109:707–712.
Wright JR: Pulmonary surfactant: a front line of lung host defense. J Clin Invest 2003, 111:1453–1455.
Seeger W, Grube C, Günther A, Schmidt R: Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J 1993, 6:971–977.
Günther A, Schmidt R, Feustel A, Meier U, Pucker C, Ermert M, Seeger W: Surfactant subtype conversion is related to loss of surfactant apoprotein B and surface activity in large surfactant aggregates. Am J Respir Crit Care Med 1999, 159:244–251.
Hawgood S: Surfactant: composition, structure, and metabolism. In The lung. Scientific foundations. 2nd edition. Edited by: Crystal RG, West JB, Weibel ER, Barnes PJ. Philadelphia:Lippincott-Raven; 1997:557–571.
Ochs M, Johnen G, Müller KM, Wahlers T, Hawgood S, Richter J, Brasch F: Intracellular and intraalveolar localization of surfactant protein A (SP-A) in the parenchymal region of the human lung. Am J Respir Cell Mol Biol 2002, 26:91–98.
Lewis JF, Novick RJ, Veldhuizen RAW: Surfactant in lung injury and lung transplantation. Austin: RG Landes; 1997.
Ikegami M, Jobe AH: Surfactant protein metabolism in vivo. Biochim Biophys Acta 1998, 1408:218–225.
Günther A, Ruppert C, Schmidt R, Markart P, Grimminger F, Walmrath D, Seeger W: Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res 2001, 2:353–364.
Clark DA, Nieman GF, Thompson JE, Paskanik AM, Rokhar JE, Bredenberg CE: Surfactant displacement by meconium free fatty acids: an alternative explanation for atelectasis in meconium aspiration syndrome. J Pediatr 1987, 110:765–770.
Moses D, Holm BA, Spitale P, Liu MY, Enhorning G: Inhibition of pulmonary surfactant function by meconium. Am J Obstet Gynecol 1991, 164:477–481.
Sun B, Curstedt T, Robertson B: Surfactant inhibition in experimental meconium aspiration. Acta Paediatr 1993, 82:182–189.
Cleary GM, Antunes MJ, Ciesielka DA, Higgins ST, Spitzer AR, Chander A: Exudative lung injury is associated with decreased levels of surfactant proteins in a rat model of meconium aspiration. Pediatrics 1997, 100:998–1003.
Kakinuma R, Shimizu H, Ogawa Y: Effect of meconium on the rate of in vitro subtype conversion of swine pulmonary surfactant. Eur J Pediatr 2002, 161:31–36.
Walther FJ: Surfactant therapy for neonatal lung disorders other than respiratory distress syndrome. In Surfactant therapy for lung disease. Lung biology in health and disease. Volume 84. Edited by: Robertson B, Taeusch HW. New York: Marcel Dekker; 1995:461–476.
Robertson B, Johansson J, Curstedt T: Synthetic surfactants to treat neonatal lung disease. Mol Med Today 2000, 6:119–124.
Taeusch HW: Treatment of acute (adult) respiratory distress syndrome. The holy grail of surfactant therapy. Biol Neonate 2000,77(suppl 1):2–8.
Wiswell TE: Expanded uses of surfactant therapy. Clinics Perinatol 2001, 28:695–711.
Curley AE, Halliday HL: The present status of exogenous surfactant for the newborn. Early Hum Dev 2001, 61:67–83.
Merrill JD, Ballard RA: Pulmonary surfactant for neonatal respiratory disorders. Curr Opin Pediatr 2003, 15:149–154.
Herting E, Rauprich P, Stichtenoth G, Walter G, Johansson J, Robertson B: Resistance of different surfactant preparations to inactivation by meconium. Pediatr Res 2001, 50:44–49.
Bae CW, Takahashi A, Chida S, Sasaki M: Morphology and function of pulmonary surfactant inhibited by meconium. Pediatr Res 1998, 44:187–191.
Taeusch HW, Lu KW, Goerke J, Clements JA: Nonionic polymers reverse inactivation of surfactant by meconium and other substances. Am J Respir Crit Care Med 1999, 159:1391–1395.
Tashiro K, Kobayashi T, Robertson B: Dextran reduces surfactant inhibition by meconium. Acta Paediatr 2000, 89:1439–1445.
Tashiro K, Cui XG, Kobayashi T, Curstedt T, Robertson B: Modified protocols for surfactant therapy in experimental meconium aspiration syndrome. Biol Neonate 2003, 83:49–56.
Kobayashi T, Ohta K, Tashiro K, Nishizuka K, Chen WM, Ohmura S, Yamamoto K: Dextran restores albumin-inhibited surface activity of pulmonary surfactant. J Appl Physiol 1999, 86:1778–1784.
Lu JJ, Cheung WWY, Yu LMY, Policova Z, Li D, Hair ML, Neumann AW: The effect of dextran to restore the activity of pulmonary surfactant inhibited by albumin. Respir Physiol Neurobiol 2002, 130:169–179.
Cui XG, Tashiro K, Matsumoto H, Tsubokawa Y, Kobayashi T: Aerosolized surfactant and dextran for experimental acute respiratory distress syndrome caused by acidified milk in rats. Acta Anaesthesiol Scand 2003, 47:853–860.
Taeusch HW, de la Serna JB, Perez-Gil J, Alonso C, Zasadzinski JA: Inhibition of pulmonary surfactant adsorption by serum and the mechanisms of reversal by hydrophilic polymers: experimental. Biophys J 2005, 89:1769–1779.
Dargaville PA, Morley CJ: Overcoming surfactant inhibition with polymers. Acta Paediatr 2000, 89:1397–1400.
Lewis JF, Veldhuizen R: The role of exogenous surfactant in the treatment of acute lung injury. Annu Rev Physiol 2003, 65:613–642.
Fehrenbach H, Brasch F, Uhlig S, Weisser M, Stamme C, Wendel A, Richter J: Early alterations in intracellular and alveolar surfactant of the rat lung in response to endotoxin. Am J Respir Crit Care Med 1998, 157:1630–1639.
Ochs M, Nenadic I, Fehrenbach A, Albes JM, Wahlers T, Richter J, Fehrenbach H: Ultrastructural alterations in intraalveolar surfactant subtypes after experimental ischemia and reperfusion. Am J Respir Crit Care Med 1999, 160:718–724.
Ochs M, Fehrenbach H, Nenadic I, Bando T, Fehrenbach A, Schepelmann D, Albes JM, Wahlers T, Richter J: Preservation of intraalveolar surfactant in a rat lung ischaemia/reperfusion injury model. Eur Respir J 2000, 15:526–531.
Bernhard W, Mottaghian J, Gebert A, Rau GA, von der Hardt H, Poets CF: Commercial versus native surfactants. Surface activity, molecular components, and the effect of calcium. Am J Respir Crit Care Med 2000, 162:1524–1533.
Schmiedl A, Krug N, Hohlfeld JM: Influence of plasma and inflammatory proteins on the ultrastructure of exogenous surfactant. J Electron Microsc 2004, 53:407–416.
Fehrenbach H, Ochs M: Studying lung ultrastructure. In Methods in pulmonary research. Edited by: Uhlig S, Taylor AE. Basel: Birkhäuser; 1998:429–454.
Howard CV, Reed MG: Unbiased stereology. Three-dimensional measurement in microscopy. 2nd edition. Oxford: Bios; 2005.
Enhorning G: Pulsating bubble technique for evaluating pulmonary surfactant. J Appl Physiol 1977, 43:198–203.
Robertson B, Taeusch HW, (Eds): Surfactant therapy for lung disease. Lung biology in health and disease. Volume 84. New York: Marcel Dekker; 1995.
Clements JA, Avery ME: Lung surfactant and neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1998, 157:S59-S66.
Greenough A: Expanded uses of surfactant replacement therapy. Eur J Pediatr 2000, 159:635–640.
Amato M, Schürch S, Grunder R, Bachofen H, Burri P: Influence of bilirubin on surface tension properties of lung surfactant. Arch Dis Child 1996, 75:F191-F196.
Schrama AJJ, de Beaufort AJ, Sukul YRM, Jansen SM, Poorthuis BJHM, Berger HM: Phospholipase A 2 is present in meconium and inhibits the activity of pulmonary surfactant: an in vitro study. Acta Paediatr 2001, 90:412–416.
Zasadzinski JA, Alig TF, Alonso C, de la Serna JB, Perez-Gil J, Taeusch HW: Inhibition of pulmonary surfactant adsorption by serum and the mechanisms of reversal by hydrophilic polymers: theory. Biophys J 2005, 89:1621–1629.
Yukitake K, Brown CL, Schlueter MA, Clements JA, Hawgood S: Surfactant apoprotein A modifies the inhibitory effect of plasma proteins on surfactant activity in vivo. Pediatr Res 1995, 37:21–25.
Strayer DS, Herting E, Sun B, Robertson B: Antibody to surfactant protein A increases sensitivity of pulmonary surfactant to inactivation by fibrinogen in vivo. Am J Respir Crit Care Med 1996, 153:1116–1122.
Chabot S, Koumanov K, Lambeau G, Gelb MH, Balloy V, Chignard M, Whitsett JA, Touqui L: Inhibitory effects of surfactant protein A on surfactant phospholipid hydrolysis by secreted phospholipases A 2 . J Immunol 2003, 171:995–1000.
Holm BA, Waring AJ: Designer surfactants. The next generation in surfactant replacement. Clinics Perinatol 1993, 20:813–829.
Lu KW, Goerke J, Clements JA, Taeusch HW: Hyaluronan reduces surfactant inhibition and improves rat lung function after meconium injury. Pediatr Res 2005, 58:206–210.
Stichtenoth G, Jung P, Walter G, Johansson J, Robertson B, Curstedt T, Herting E: Polymyxin B/pulmonary surfactant mixtures have increased resistance to inactivation by meconium and reduce growth of gram-negative bacteria in vitro. Pediatr Res 2006, 59:407–411.